LAWLIS V BRYAN 4
4 · BIOMARIN PHARMACEUTICAL INC · Filed Apr 18, 2022
Insider Transaction Report
Form 4
LAWLIS V BRYAN
Director
Transactions
- Exercise/Conversion
Common Stock
2022-04-14$37.46/sh+4,250$159,205→ 28,220 total - Exercise/Conversion
Stock Option (Right to buy Common Stock)
2022-04-14−4,250→ 0 totalExercise: $37.46From: 2012-11-08Exp: 2022-05-07→ Common Stock (4,250 underlying) - Sale
Common Stock
2022-04-14$83.66/sh−4,250$355,555→ 23,970 total
Footnotes (2)
- [F1]Trade made pursuant to a 10b5-1 plan executed on July 29, 2021.
- [F2]Reflects the number of options outstanding after the transactions from this specific stock option grant.